CD274 and ovarian cancer: Of the 11 ongoing randomised phase 3 trials evaluating anti-PD-L1 agents in earlier-staged cancers as adjuvant (postoperative) or neoadjuvant (preoperative) therapies, there is also one ovarian cancer trial that includes an antiangiogenic drug in the investigational drug combination (Suppl.